Brief: Zyversa Therapeutics On Feb 29, Got Nasdaq Approval To Transfer Listing Of Co’S Common Stock From Nasdaq Global Market To Nasdaq Capital Market
01/03/2024 21:36
March 1 (Reuters) - Zyversa Therapeutics Inc ZVSA.O :
* ZYVERSA THERAPEUTICS: ON FEB 29, GOT NASDAQ APPROVAL TO
TRANSFER
LISTING OF CO’S COMMON STOCK FROM NASDAQ GLOBAL MARKET TO NASDAQ
CAPITAL MARKET
Further company coverage: ZVSA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zyversa Therapeutics
See all newsBrief: ZyVersa Therapeutics Announces Share Purchase Agreement for up to $10 Million
Brief: ZyVersa Unveils Potential Of Inflammasome Inhibitors In Combination With GLP-1 Agonists To Address Needs Of People Living With Obesity
Brief: Zyversa Therapeutics Announces Published Data Showing Inflammasome Asc Inhibitor IC 100 Decreases Microglial Inflammasome Activation
Brief: ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative Research And Development Trends For Inflammasome Inhibitors, And Provides Update On Inflammasome ASC Inhibitor IC 100’S Development Status
Brief: Zyversa Therapeutics Files For Prospectus Related To Offer & Resale Of Up To 1.6 Million Shares Of Common Stock By Selling Stockholder - SEC Filing